Structure of a low-population intermediate state in the release of an enzyme product

Alfonso De Simone, Francesco A. Aprile, Anne Dhulesia, Christopher M. Dobson, Michele VendruscoloeLife 2014 · DOI

TL;DR

Researchers have determined the atomic-level structure of a fleeting, low-population intermediate state involved in human lysozyme's product release. This breakthrough, achieved through a combination of NMR spectroscopy and molecular dynamics, reveals how transient conformational changes facilitate enzyme function and opens doors for understanding similar processes in other enzymes.

What Problem Does This Paper Address?

Enzymes are biological catalysts that speed up reactions by binding substrates and converting them into products. While the initial binding and the chemical transformation are well-studied, the final step – product release – is often rate-limiting and poorly understood. This is because the intermediate conformations involved in product release are extremely transient and exist at very low populations, making them incredibly difficult to capture and characterize using traditional structural biology techniques. Understanding these fleeting states is crucial for a complete picture of enzyme mechanisms and for designing more efficient enzymes.

Methods

The core of this study lies in a sophisticated integration of experimental and computational techniques:

  • Nuclear Magnetic Resonance (NMR) Spectroscopy: Specifically, Residual Dipolar Couplings (RDCs) were employed. RDCs provide long-range orientational information about molecular structures, acting as powerful restraints for structural determination, especially for dynamic or low-population states.
  • Molecular Dynamics (MD) Simulations: The RDC data was used to guide MD simulations. This approach, known as replica-averaged RDC restraints, allows for the exploration and sampling of conformational ensembles that are consistent with the experimental NMR data. This is particularly effective for capturing low-population states that would be missed by standard MD.
  • Rational Mutagenesis: To validate the proposed intermediate structure, the researchers designed specific mutations in the lysozyme enzyme. One mutation was engineered to destabilize the identified intermediate, while another was designed to stabilize it. The effects of these mutations on product release kinetics were then experimentally measured.

What's novel here is the application of RDC-guided MD to specifically target and characterize a low-population intermediate state involved in product release, a feat that has been challenging for many years.

Datasets

The study utilized existing structural data for human lysozyme:

  • Crystal structure of human lysozyme at 1.9 Å resolution (PDB code 2ZIJ).
  • Crystal structure of the human lysozyme A96L variant bound to triNAG at 1.8 Å resolution (PDB code 1BB5).

No new datasets were introduced; rather, existing structural information was leveraged and refined through the experimental and computational methods described.

Key Insights and Ideas

  • Product Release is Facilitated by a Metastable Intermediate: The study provides strong evidence that the release of a product from human lysozyme doesn't happen in a single step but proceeds through a transient, low-population intermediate state. This "unlocked" state, distinct from the primary "locked" state, is crucial for efficient product release.
  • Concerted Domain Motion Drives the Intermediate: Large-scale conformational changes, specifically a "breathing" motion involving the alpha and beta domains of lysozyme, are responsible for generating this unlocked intermediate. This motion alters the enzyme's active site, weakening interactions with the product.
  • A Specific Hydrogen Bond Stabilizes the Intermediate: A key structural feature of the unlocked intermediate is a transient hydrogen bond between residues N44 (beta-domain) and E35 (alpha-domain). This interaction is absent in the ground state and specifically stabilizes the intermediate conformation.
  • Mutations Confirm the Role of the Intermediate: The experimental validation through mutagenesis powerfully supports the findings. Destabilizing the hydrogen bond (N44A mutation) significantly slowed down product release, while stabilizing it (hypothetically, though the described stabilization mutation showed a different effect) would be expected to speed it up. This demonstrates a direct link between the intermediate's stability and the enzyme's catalytic efficiency.

Key Results

  • Identification of an "Unlocked" Intermediate State: The free-energy landscape analysis revealed a distinct, low-population (approx. 13%) "unlocked" state in the triNAG-bound lysozyme, characterized by a different domain orientation (θ ≈ 49°) compared to the dominant "locked" state (θ ≈ 58°).
  • Characterization of a Stabilizing Hydrogen Bond: A specific hydrogen bond between N44 and E35 was identified as a key feature of the unlocked state, absent in the locked state.
  • Mutational Impact on Product Release:
    • The N44A mutation (destabilizing the intermediate) reduced the product release rate (koff) by a factor of 3 and altered the binding affinity (Ka) by a factor of 1/3, while also affecting substrate capture (kon). Cellular assays showed intermediate activity for the N44A mutant compared to wild-type and a catalytically inactive mutant.
  • The N46Q/V110Q mutation (designed to stabilize the unlocked state) resulted in a significantly higher binding affinity (Kᵢ) for the ligand, indicating that the mutant essentially does not bind the substrate, consistent with the idea that stabilizing the intermediate might hinder binding.

Limitations and Future Work

  • Focus on Product Release: This study specifically addresses the product release step. The authors suggest that future work should focus on characterizing the intermediate states involved in substrate capture and the transition state.
  • Generalizability to Other Enzymes: While the findings are significant for lysozyme, extending this approach to characterize similar low-population intermediates in other enzymes is a key future direction.
  • Computational Accuracy: While RDC-guided MD is powerful, the accuracy of the resulting ensembles is dependent on the force field and simulation parameters. The authors performed extensive validation to mitigate this.
  • Further Stabilization Studies: The stabilization mutation (N46Q/V110Q) showed an unexpected effect on binding affinity, suggesting that stabilizing the intermediate might not always lead to faster release if it also impedes initial substrate binding. Further investigation into the interplay between intermediate stability and substrate binding is warranted.

Summary updated

Abstract

Enzymes can increase the rate of biomolecular reactions by several orders of magnitude. Although the steps of substrate capture and product release are essential in the enzymatic process, complete atomic-level descriptions of these steps are difficult to obtain because of the transient nature of the intermediate conformations, which makes them largely inaccessible to standard structure determination methods. We describe here the determination of the structure of a low-population intermediate in the product release process by human lysozyme through a combination of NMR spectroscopy and molecular dynamics simulations. We validate this structure by rationally designing two mutations, the first engineered to destabilise the intermediate and the second to stabilise it, thus slowing down or speeding up, respectively, product release. These results illustrate how product release by an enzyme can be facilitated by the presence of a metastable intermediate with transient weak interactions between the enzyme and product.
BibTeX
@inproceedings{simone2014structure,
  author = {Alfonso De Simone and Francesco A. Aprile and Anne Dhulesia and Christopher M. Dobson and Michele Vendruscolo},
  title = {{Structure of a low-population intermediate state in the release of an enzyme product}},
  booktitle = {eLife},
  year = {2014},
  doi = {10.7554/elife.02777},
}
Figure